# US 2003/0215827 A1 · Aminoacyl trna synthetases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0215827 A1
- Document ID: US20030215827A1
- Status: Published application
- Kind: A1
- Application number: 10/296,540
- Filed: 2003-04-07
- Published: 2003-11-20
- Earliest claimed: 2003-04-07
- Inventors: Henry Yue; Y Tom Tang; Chandra Patterson; Ameena R Gandhi; Catherine M Tribouley; Ernestine A Lee; Monique G Yao; Olga Bandman; Dyung Alina M Lu
- Web page: https://patentgrep.com/patent/US20030215827A1

## CPC

- C12N 9/93: {Ligases (6)}
- C07H 21/04: with deoxyribosyl as saccharide radical
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The invention provides human aminoacyl TRNA synthetases (ATRS) and polynucleotides which identify and encode ATRS. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of ATRS.

## Claims

### Claim 1

An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-4,
b) a naturally occurring polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 1-4,
c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4, and
d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4.

### Claim 2 (depends on 1)

An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-4.

### Claim 3 (depends on 1)

An isolated polynucleotide encoding a polypeptide of claim 1.

### Claim 4 (depends on 2)

An isolated polynucleotide encoding a polypeptide of claim 2.

### Claim 5 (depends on 4)

An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:5-8.

### Claim 6 (depends on 3)

A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

### Claim 7 (depends on 6)

A cell transformed with a recombinant polynucleotide of claim 6.

### Claim 8 (depends on 6)

A transgenic organism comprising a recombinant polynucleotide of claim 6.

### Claim 9 (depends on 1)

A method for producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
b) recovering the polypeptide so expressed.

### Claim 10 (depends on 1)

An isolated antibody which specifically binds to a polypeptide of claim 1.

### Claim 11

An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:5-8,
b) a naturally occurring polynucleotide comprising a polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:5-8,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).

### Claim 12 (depends on 11)

An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

### Claim 13 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

### Claim 14 (depends on 13)

A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

### Claim 15 (depends on 11)

A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

### Claim 16 (depends on 1)

A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 16)

A composition of claim 16, wherein the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO:1-4.

### Claim 18 (depends on 16)

A method for treating a disease or condition associated with decreased expression of functional ATRS, comprising administering to a patient in need of such treatment the composition of claim 16.

### Claim 19 (depends on 1)

A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

### Claim 20 (depends on 19)

A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

### Claim 21 (depends on 20)

A method for treating a disease or condition associated with decreased expression of functional ATRS, comprising administering to a patient in need of such treatment a composition of claim 20.

### Claim 22 (depends on 1)

A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

### Claim 23 (depends on 22)

A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

### Claim 24 (depends on 23)

A method for treating a disease or condition associated with overexpression of functional ATRS, comprising administering to a patient in need of such treatment a composition of claim 23.

### Claim 25 (depends on 1)

A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

### Claim 26 (depends on 1)

A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

### Claim 27 (depends on 5)

A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
b) detecting altered expression of the target polynucleotide, and
c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

### Claim 28 (depends on 11)

A method for assessing toxicity of a test compound, said method comprising:
a) treating a biological sample containing nucleic acids with the test compound;
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
c) quantifying the amount of hybridization complex; and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

### Claim 29 (depends on 10)

A diagnostic test for a condition or disease associated with the expression of ATRS in a biological sample comprising the steps of:
a) combining the biological sample with an antibody of claim 10, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex; and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

### Claim 30 (depends on 10)

The antibody of claim 10, wherein the antibody is:
a) a chimeric antibody,
b) a single chain antibody,
c) a Fab fragment,
d) a F(ab′)2 fragment, or
e) a humanized antibody.

### Claim 31 (depends on 10)

A composition comprising an antibody of claim 10 and an acceptable excipient.

### Claim 32 (depends on 31)

A method of diagnosing a condition or disease associated with the expression of ATRS in a subject, comprising administering to said subject an effective amount of the composition of claim 31.

### Claim 33 (depends on 31)

A composition of claim 31, wherein the antibody is labeled.

### Claim 34 (depends on 33)

A method of diagnosing a condition or disease associated with the expression of ATRS in a subject, comprising administering to said subject an effective amount of the composition of claim 33.

### Claim 35 (depends on 10)

A method of preparing a polyclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibodies from said animal; and
c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide having an aniino acid sequence selected from the group consisting of SEQ ID NO:1-4.

### Claim 36 (depends on 35)

An antibody produced by a method of claim 35.

### Claim 37 (depends on 36)

A composition comprising the antibody of claim 36 and a suitable carrier.

### Claim 38 (depends on 10)

A method of making a monoclonal antibody with the specificity of the antibody of claim 10 comprising:
a) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4, or an immunogenic fragment thereof, under conditions to elicit an antibody response;
b) isolating antibody producing cells from the animal;
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
d) culturing the hybridoma cells; and
e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4.

### Claim 39 (depends on 38)

A monoclonal antibody produced by a method of claim 38.

### Claim 40 (depends on 39)

A composition comprising the antibody of claim 39 and a suitable carrier.

### Claim 41 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a Fab expression library.

### Claim 42 (depends on 10)

The antibody of claim 10, wherein the antibody is produced by screening a recombinant immunoglobulin library.

### Claim 43 (depends on 10)

A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4 in a sample, comprising the steps of:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-4 in the sample.

### Claim 44 (depends on 10)

A method of purifying a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4 from a sample, the method comprising:
a) incubating the antibody of claim 10 with a sample under conditions to allow specific binding of the antibody and the polypeptide; and
b) separating the antibody from the sample and obtaining the purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-4.

### Claim 45 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

### Claim 46 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:2.

### Claim 47 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

### Claim 48 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

### Claim 49 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:5.

### Claim 50 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:6.

### Claim 51 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:7.

### Claim 52 (depends on 11)

A polynucleotide of claim 11, comprising the polynucleotide sequence of SEQ ID NO:8.
